Samsung Bioepis Moves Eylea Biosimilar To Phase III

Multiple Phase III Trials For Aflibercept Candidate In Progress

 
• By Dean Rudge
  
Eye
Samsung now has now pushed two ophthalmic biosimilars into Phase III trials • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products